VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme

Aleksandra Gruslova, David A. Cavazos, Jessica R. Miller, Eyal Breitbart, Yael C. Cohen, Livnat Bangio, Niva Yakov, Anu Soundararajan, John R. Floyd, Andrew J. Brenner

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Glioblastoma multiforme (GBM) is among the most highly vascularized of solid tumors, contributing to the infiltrative nature of the disease, and conferring poor outcome. Due to the critical dependency of GBM on growth of new endothelial vasculature, we evaluated the preclinical activity of a novel adenoviral gene therapy that targets the endothelium within newly formed blood vessels for apoptosis. VB-111, currently in phase II clinical trials, consists of a non-replicating Adenovirus 5 (El deleted) carrying a proapoptotic human Fas-chimera (transgene) under the control of a modified murine promoter (PPE-1-3×) which specifically targets endothelial cells within the tumor vasculature. Here we report that a single intravenous dose of 2.5 × 1011 or 1 × 1011 VPs was sufficient to extend survival in nude rats bearing U87MG-luc2 or nude mice bearing U251-luc, respectively. Bioluminescence imaging of nude rats showed that VB-111 effectively inhibited tumor growth within four weeks of treatment. This was confirmed in a select group of animals by MRI. In our mouse model we observed that 3 of 10 nude mice treated with VB-111 completely lost U251 luciferase signal and were considered long term survivors. To assess the antiangiogenic effects of VB-111, we evaluated the tumor-associated microvaculature by CD31, a common marker of neovascularization, and found a significant decrease in the microvessel density by IHC. We further assessed the neovasculature by confocal microscopy and found that VB-111 inhibits vascular density in two separate mouse models bearing U251-RFP xenografts. Collectively, this study supports the clinical development of VB-111 as a treatment for GBM.

Original languageEnglish
Pages (from-to)365-372
Number of pages8
JournalJournal of Neuro-Oncology
Issue number3
StatePublished - 30 Sep 2015
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015, Springer Science+Business Media New York.


The study was supported by in part by the UTHSCSA Cancer Therapy and Research Center through the National Institutes of Health National Cancer Institute P30 award CA054174, as well as by a service agreement with VBL Therapeutics.

FundersFunder number
National Cancer Institute
National Institutes of Health
UTHSCSA Cancer Therapy and Research Center
University of Texas Health Science Center at San Antonio
National Institutes of HealthCA054174, L30CA154152


    • Angiogenesis
    • Gene therapy
    • Glioblastoma
    • Tumor vasculature
    • VB-111


    Dive into the research topics of 'VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme'. Together they form a unique fingerprint.

    Cite this